Market Cap 20.69B
Revenue (ttm) 4.24B
Net Income (ttm) 32.61M
EPS (ttm) N/A
PE Ratio 20.35
Forward PE 18.63
Profit Margin 0.77%
Debt to Equity Ratio 0.00
Volume 2,035,000
Avg Vol 2,173,470
Day's Range N/A - N/A
Shares Out 196.32M
Stochastic %K 45%
Beta 0.74
Analysts Sell
Price Target $95.14

Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a select...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 498 6700
Address:
1801 Augustine Cut-Off, Wilmington, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 8:36 AM
$INCY is currently trading at $104.15, showing a strong upward momentum with an RSI of 71.22, indicating it is in overbought territory. The price is above both the 30-day moving average (MA30) of $93.95 and the 50-day moving average (MA50) of $90.34, signaling bullish sentiment. However, the high of $109.28 from the last 60 days suggests potential resistance ahead. Given the current metrics, the directional bias is cautiously bullish but requires careful monitoring due to the high RSI. Suggested entry could be around $102.50, slightly below the current price to confirm continued strength. A stop loss should be set at $98.00 to manage risk effectively. Targets can be set at $107.00, near the 60D high, and a more aggressive target at $110.00, should momentum persist. Monitor for any signs of reversal as the price approaches these targets. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 11:57 PM
$INCY: The current market context shows a last close of $104.15, with an RSI of 71.22, indicating overbought conditions. The price is above both the 30-day MA of 93.95 and the 50-day MA of 90.34, suggesting a bullish trend. However, the high of $109.28 within the last 60 days presents a resistance level that may limit upside potential. Directional bias leans bearish in the short term due to the overbought RSI, indicating a possible pullback. Suggested entry point is around $102.50, just below current levels to capitalize on a potential retracement. Set a stop loss at $100.00 to manage risk. Target 1 is $108.00, approaching the 60D high, while Target 2 is $110.00 if momentum resumes. Monitor price action closely, as a breach of the stop could indicate a stronger downtrend. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
OptionRunners
OptionRunners Nov. 14 at 6:19 PM
$INCY Buyer of the December 19th $105 puts 1,500 times for $6.10-$6.35
0 · Reply
_Verticality
_Verticality Nov. 14 at 8:45 AM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:30 AM
$INCY is currently trading at $105.41, exhibiting a strong bullish momentum as indicated by an RSI of 76.53, suggesting it is overbought. The price is well above its 30-day moving average (MA30) of 93.37 and 50-day moving average (MA50) of 89.99, reinforcing the upward trend. However, the high RSI indicates potential for a pullback, especially as it approaches the 60-day high of $109.28. Trade Plan: - Directional Bias: Bullish, but cautious due to overbought conditions. - Suggested Entry: $105.00 (to capture potential pullback). - Stop Loss: $101.75 (below recent support levels). - Target 1: $108.00 (near 60D high). - Target 2: $110.00 (psychological resistance level). Monitor RSI for signs of reversal and adjust targets accordingly. This strategy balances capturing upside potential while managing risk due to current overbought conditions. https://privateprofiteers.com
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 13 at 4:29 PM
The attachment compares $SNDX valuation at $15.19 a share as a multiple of analyst revenue estimates versus commercial-stage oncology & non-oncology focused peers with similar revenue estimates Only God knows what will happen to SNDX's share price in the near-term with KURA's approval Longer term, we hope KURA's approval eliminates any nagging overhang on SNDX's risk v reward profile. Ideally, the market can now assign SNDX a valuation consistent with peer multiples On the $INCY front, INCY trades at a FY29 revenue multiple more than 3X higher than SNDX. This is the year after INCY's Jakafi patent expires. Hence, Incyte is obligated to its shareholders to at least consider SNDX. Incyte's CEO was on the BOD at SNDX & there is no longer any need to wait for KURA. An agreed M&A share price can be agreed to over a steak dinner. Bottom line, we suspect if INCY has not agreed to acquire SNDX by JP Morgan in early Jan 2026 then it will not happen. Just 1 investor's perspective
3 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 13 at 1:48 AM
$SNDX Revuforj product sales by quarter post launch versus 3 peer therapies acquired for $1.7 to $1.9B attached. Revuforj was only approved for its KMT2A label during these 4 quarters. Revuforj's mNPM1 label came in Revuforj's 5th quarter on the market. Raw sales data to the lower right. Revuforj, when only approved for KMT2A leukemias, comfortably outsold all 3 products. We post considerable SNDX analysis here on STs but this one could be especially meaningful If new drugs are worth some multiple of actual sales, and Revuforj is outselling these 3 drugs by factors of 1.2 to 1.8X then, by itself, these data points suggest Revuforj in only its KMT2A label is worth north of $2B. This is not investment advice as obviously there are multiple other data points to consider but actual sales are meaningful. Imagine the value Revuforj's mNPM1 label could bring to SNDX's valuation profile. Obviously, Niktimvo (50/50 with $INCY ) is also not considered. Pushback? $AVDL ? $XBI $IBB
2 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:37 AM
$INCY: The last close at $107.67 indicates a strong upward trend, but the RSI at 87.13 suggests that the stock is overbought, which may lead to a pullback. The MA30 at 92.0 and MA50 at 89.15 further confirm bullish momentum, yet the significant distance from these MAs raises caution regarding sustainability. The 60D high of 108.81 is just above the current price, which could act as a resistance level, while the 60D low of 81.09 provides a solid support reference. Directional bias is cautiously bullish, but the overbought RSI signals potential short-term weakness. Suggested entry is at $106.50, just below the last close, to capitalize on a potential dip. Set a stop at $104.00 to manage risk. Target 1 is $110.00, aligning with a psychological resistance level, and Target 2 is $112.00, anticipating further upward movement if momentum resumes. https://privateprofiteers.com
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Nov. 13 at 1:29 AM
$INCY if I used TA or flow or gambled I would have sold the bottom here but using math and data and well there ya go. Grats longs
0 · Reply
JFais
JFais Nov. 12 at 6:26 PM
If $INCY were to make a move on $SNDX, $30 share price ($2.7B market cap /$2.3B EV) seems reasonable today Later in 2026, price tag goes up as NPM1 launch progresses, more patients return to Revuforj post transplant & frontline data (SAVE/BEAT) makes its way to NCCN guidelines
2 · Reply
Latest News on INCY
Top Biotech Stocks Riding The Rally

Nov 4, 2025, 3:15 PM EST - 10 days ago

Top Biotech Stocks Riding The Rally

CTMX GRAL GRFS


Incyte to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:00 AM EDT - 16 days ago

Incyte to Present at Upcoming Investor Conferences


Incyte Corporation (INCY) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 11:41 AM EDT - 18 days ago

Incyte Corporation (INCY) Q3 2025 Earnings Call Transcript


Incyte: Strong Growth, Margin Expansion, And Low Valuation

Oct 21, 2025, 11:13 PM EDT - 24 days ago

Incyte: Strong Growth, Margin Expansion, And Low Valuation


3 Biotech Stocks I Am Accumulating

Oct 15, 2025, 2:30 PM EDT - 4 weeks ago

3 Biotech Stocks I Am Accumulating

ADMA HRMY SNDX XBI


Incyte to Report Third Quarter Financial Results

Oct 8, 2025, 8:00 AM EDT - 5 weeks ago

Incyte to Report Third Quarter Financial Results


3 Potential Biotech Acquisition Targets

Sep 19, 2025, 12:53 PM EDT - 2 months ago

3 Potential Biotech Acquisition Targets

AZN ETNB MLYS SNDX TVTX


US FDA approves Incyte's eczema treatment for pediatric patients

Sep 18, 2025, 4:29 PM EDT - 2 months ago

US FDA approves Incyte's eczema treatment for pediatric patients


Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 1:33 PM EDT - 3 months ago

Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript


Incyte to Report Second Quarter Financial Results

Jul 10, 2025, 8:00 AM EDT - 4 months ago

Incyte to Report Second Quarter Financial Results


PrivateProfiteer
PrivateProfiteer Nov. 15 at 8:36 AM
$INCY is currently trading at $104.15, showing a strong upward momentum with an RSI of 71.22, indicating it is in overbought territory. The price is above both the 30-day moving average (MA30) of $93.95 and the 50-day moving average (MA50) of $90.34, signaling bullish sentiment. However, the high of $109.28 from the last 60 days suggests potential resistance ahead. Given the current metrics, the directional bias is cautiously bullish but requires careful monitoring due to the high RSI. Suggested entry could be around $102.50, slightly below the current price to confirm continued strength. A stop loss should be set at $98.00 to manage risk effectively. Targets can be set at $107.00, near the 60D high, and a more aggressive target at $110.00, should momentum persist. Monitor for any signs of reversal as the price approaches these targets. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 11:57 PM
$INCY: The current market context shows a last close of $104.15, with an RSI of 71.22, indicating overbought conditions. The price is above both the 30-day MA of 93.95 and the 50-day MA of 90.34, suggesting a bullish trend. However, the high of $109.28 within the last 60 days presents a resistance level that may limit upside potential. Directional bias leans bearish in the short term due to the overbought RSI, indicating a possible pullback. Suggested entry point is around $102.50, just below current levels to capitalize on a potential retracement. Set a stop loss at $100.00 to manage risk. Target 1 is $108.00, approaching the 60D high, while Target 2 is $110.00 if momentum resumes. Monitor price action closely, as a breach of the stop could indicate a stronger downtrend. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
OptionRunners
OptionRunners Nov. 14 at 6:19 PM
$INCY Buyer of the December 19th $105 puts 1,500 times for $6.10-$6.35
0 · Reply
_Verticality
_Verticality Nov. 14 at 8:45 AM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 3:30 AM
$INCY is currently trading at $105.41, exhibiting a strong bullish momentum as indicated by an RSI of 76.53, suggesting it is overbought. The price is well above its 30-day moving average (MA30) of 93.37 and 50-day moving average (MA50) of 89.99, reinforcing the upward trend. However, the high RSI indicates potential for a pullback, especially as it approaches the 60-day high of $109.28. Trade Plan: - Directional Bias: Bullish, but cautious due to overbought conditions. - Suggested Entry: $105.00 (to capture potential pullback). - Stop Loss: $101.75 (below recent support levels). - Target 1: $108.00 (near 60D high). - Target 2: $110.00 (psychological resistance level). Monitor RSI for signs of reversal and adjust targets accordingly. This strategy balances capturing upside potential while managing risk due to current overbought conditions. https://privateprofiteers.com
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 13 at 4:29 PM
The attachment compares $SNDX valuation at $15.19 a share as a multiple of analyst revenue estimates versus commercial-stage oncology & non-oncology focused peers with similar revenue estimates Only God knows what will happen to SNDX's share price in the near-term with KURA's approval Longer term, we hope KURA's approval eliminates any nagging overhang on SNDX's risk v reward profile. Ideally, the market can now assign SNDX a valuation consistent with peer multiples On the $INCY front, INCY trades at a FY29 revenue multiple more than 3X higher than SNDX. This is the year after INCY's Jakafi patent expires. Hence, Incyte is obligated to its shareholders to at least consider SNDX. Incyte's CEO was on the BOD at SNDX & there is no longer any need to wait for KURA. An agreed M&A share price can be agreed to over a steak dinner. Bottom line, we suspect if INCY has not agreed to acquire SNDX by JP Morgan in early Jan 2026 then it will not happen. Just 1 investor's perspective
3 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 13 at 1:48 AM
$SNDX Revuforj product sales by quarter post launch versus 3 peer therapies acquired for $1.7 to $1.9B attached. Revuforj was only approved for its KMT2A label during these 4 quarters. Revuforj's mNPM1 label came in Revuforj's 5th quarter on the market. Raw sales data to the lower right. Revuforj, when only approved for KMT2A leukemias, comfortably outsold all 3 products. We post considerable SNDX analysis here on STs but this one could be especially meaningful If new drugs are worth some multiple of actual sales, and Revuforj is outselling these 3 drugs by factors of 1.2 to 1.8X then, by itself, these data points suggest Revuforj in only its KMT2A label is worth north of $2B. This is not investment advice as obviously there are multiple other data points to consider but actual sales are meaningful. Imagine the value Revuforj's mNPM1 label could bring to SNDX's valuation profile. Obviously, Niktimvo (50/50 with $INCY ) is also not considered. Pushback? $AVDL ? $XBI $IBB
2 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 1:37 AM
$INCY: The last close at $107.67 indicates a strong upward trend, but the RSI at 87.13 suggests that the stock is overbought, which may lead to a pullback. The MA30 at 92.0 and MA50 at 89.15 further confirm bullish momentum, yet the significant distance from these MAs raises caution regarding sustainability. The 60D high of 108.81 is just above the current price, which could act as a resistance level, while the 60D low of 81.09 provides a solid support reference. Directional bias is cautiously bullish, but the overbought RSI signals potential short-term weakness. Suggested entry is at $106.50, just below the last close, to capitalize on a potential dip. Set a stop at $104.00 to manage risk. Target 1 is $110.00, aligning with a psychological resistance level, and Target 2 is $112.00, anticipating further upward movement if momentum resumes. https://privateprofiteers.com
0 · Reply
AdamURAtoFookingNeptune
AdamURAtoFookingNeptune Nov. 13 at 1:29 AM
$INCY if I used TA or flow or gambled I would have sold the bottom here but using math and data and well there ya go. Grats longs
0 · Reply
JFais
JFais Nov. 12 at 6:26 PM
If $INCY were to make a move on $SNDX, $30 share price ($2.7B market cap /$2.3B EV) seems reasonable today Later in 2026, price tag goes up as NPM1 launch progresses, more patients return to Revuforj post transplant & frontline data (SAVE/BEAT) makes its way to NCCN guidelines
2 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 1:13 AM
$INCY: The last close at $107.67 indicates a strong upward trend, but the RSI at 87.13 suggests that the stock is overbought, which may lead to a pullback. The MA30 at 92.0 and MA50 at 89.15 further confirm bullish momentum, yet the significant distance from these MAs raises caution regarding sustainability. The 60D high of 108.81 is just above the current price, which could act as a resistance level, while the 60D low of 81.09 provides a solid support reference. Directional bias is cautiously bullish, but the overbought RSI signals potential short-term weakness. Suggested entry is at $106.50, just below the last close, to capitalize on a potential dip. Set a stop at $104.00 to manage risk. Target 1 is $110.00, aligning with a psychological resistance level, and Target 2 is $112.00, anticipating further upward movement if momentum resumes. https://privateprofiteers.com
0 · Reply
judgeyoung2
judgeyoung2 Nov. 11 at 7:04 PM
$INCY The Phase 3 study evaluating tafasitamab (Monjuvi®) as first-line treatment for diffuse large B-cell lymphoma (DLBCL) is ongoing, with data anticipated around year-end 2025.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 11 at 5:06 PM
$INCY v $SNDX FY2029 (Year 4) revenue multiples and a snap shot of the peer Year 4 M&A revenue multiples paid in 6 transactions deemed by Centerview Partners as appropriate peers for the SWTX acquisition. This is not investment advice. The SWTX peers may not be appropriate for SNDX. Note even at $17.05/share, SNDX trades for 1.5X FY2029 (Year 4) analyst consensus. The 6 SWTX peers were acquired for a median 3.8X Year 4 revenue multiple (average was 3.9X). Note 5 of the 6 peers were acquired for multiples ranging from 3.4X to 5.2X. There was one outlier at 2.3X which is still 50% higher than SNDX at $17.05/share. Can anyone share why SNDX & SWTX are not good peers? Both had 2 FDA approved therapies INCY & SNDX are 50/50 partners in Niktimvo (US). INCY trades at 4.8X FY2029 consensus (the year after Jakafi's patent expires). $XBI $IBB
0 · Reply
aaxaa
aaxaa Nov. 10 at 4:22 PM
$BLCO $INCY twinning?
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 10 at 3:19 PM
$SNDX There is no bigger fan of SNDX than the 3 of us who run our little investment club...and me the one that makes 98% of our posts. We are practically giddy with this morning's gains. Even at $16.35/share SNDX trades at a very low multiple of projected revenues versus peers with similar revenue forecasts. The attachment shows just that. We only caution investors as, time & again recently, SNDX sees large gains in the morning only to be, what appears to be, taken down deliberately & intentionally by the end of the day. Or is today the day we finally break higher. This is not investment advice. We have no idea what will happen to SNDX's share price. $INCY $XBI $IBB
2 · Reply
GorillaTrades
GorillaTrades Nov. 7 at 8:30 PM
$RMBS Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Incyte $INCY +12.8%, STERIS $STE +12.0%, and Hamilton Insurance $HG +9.6%
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 7 at 4:27 PM
$SNDX continues to trade at a fraction of the valuation of peer commercial-stage oncology & non-oncology focused bios with similar projected revenue profiles. SNDX's year-to-date gross margin is ~96%. This is ultra-competitive. Revuforj is a pill. Niktimvo is administered via IV. The SNDX phenomenon is outrageous unless all 5 analysts who provide SNDX FY2029 revenue estimates are dead wrong, but of course only wrong about SNDX & not the dozen or so peers. SNDX's management & BOD are ultimately only responsible to ensure shareholder value is maximized. Should SNDX continue to trade at multiples of revenues far below peers then SNDX is obligated to consider alternative strategies to enhance share price, including a sale of the company. SNDX Niktimvo partner $INCY now trades at 4.7X FY2029 revenue estimates that include Niktimvo but after Jakafi's patents expire in 12/2028...versus SNDX at 1.3X that also includes Niktimvo This is not investment advice. $XBI $IBB
2 · Reply
teksviler
teksviler Nov. 6 at 7:53 PM
$LFLR.CSE Brand new holding for me. $AEM long and strong. Recent additions $AMKR and $INCY . Let's roll 👊
0 · Reply
teksviler
teksviler Nov. 6 at 2:01 PM
$PODD $INCY $CCCX $MU Long and strong 💪 LLG
0 · Reply
modrica3
modrica3 Nov. 5 at 8:58 PM
$INCY $PRLD exactly , they got $25 mill at $4 per share they got $35 mill cash and per last q they had arou d $77 mill cash already selling at 1.40 ? hhhmmm
0 · Reply
FireIn
FireIn Nov. 5 at 8:54 PM
$PRLD $60M upfront (35M cash + 25M equity) deal with $INCY for JAK2 V617F inhibitor program + up to ~$910M in milestones & royalties. This is strong validation for Prelude’s pipeline.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 5 at 2:29 PM
Attached is a copy of hypothetical $SNDX M&A values per share assuming 1. SNDX lowest, consensus & highest FY2029 (Year 4) analyst revenue estimate of 5 analysts 2. Lowest, median & highest peer Year 4 M&A revenue multiples paid in 6 M&A transaction cited by Centerview Partners as appropriate peers for SWTX. Just remember SWTX may not be an appropriate peer for SNDX 3. SNDX actual 9/30/2025 cap table. Share activity post 9/30/25 are not reflected. The attachment is completely driven by the assumptions and "what-ifs." We've provided the original sources of these assumptions. This is not investment advice. We're only sharing the corresponding math using SNDX's 9/30/2025 cap table. The range of hypothetical M&A share prices is so broad it is almost non-useful. SNDX investors should decide for themselves what are the appropriate assumptions. $INCY $XBI $IBB $NBI
1 · Reply